Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor

Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

1 - 29 . (canceled) 
     
     
         30 . A method for treating multiple myeloma in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein a starting dose of the escalating doses is less than 300 mg per day and an ending dose of the escalating doses is 300 mg per day. 
     
     
         31 . The method of  claim 30 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles, and each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         32 . The method of  claim 30 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab, and the effective amount of the obinutuzumab is 1000 mg. 
     
     
         33 . The method of  claim 32 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 in multiple dosing cycles, and the effective amount of the obinutuzumab is administered once in each dosing cycle for 6 to 7 dosing cycles of the multiple dosing cycles. 
     
     
         34 . The method of  claim 30 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone. 
     
     
         35 . The method of  claim 33 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         36 . The method of  claim 30 , wherein the multiple myeloma is refractory multiple myeloma. 
     
     
         37 . The method of  claim 30 , wherein the method is continued until disease progression. 
     
     
         38 . A method for treating multiple myeloma in a human patient, the method comprising orally administering a once daily dose of GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise a dose of less than 300 mg per day followed by a dose of 300 mg per day. 
     
     
         39 . The method of  claim 38 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles. 
     
     
         40 . The method of  claim 39 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         41 . The method of  claim 39 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab. 
     
     
         42 . The method of  claim 41 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         43 . The method of  claim 42 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 once in each dosing cycle for 6 to 7 dosing cycles. 
     
     
         44 . The method of  claim 41 , wherein the effective amount of the obinutuzumab is 1000 mg. 
     
     
         45 . The method of  claim 39 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone. 
     
     
         46 . The method of  claim 45 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         47 . The method of  claim 38 , wherein the multiple myeloma is refractory multiple myeloma. 
     
     
         48 . The method of  claim 38 , wherein the method is continued until disease progression. 
     
     
         49 . A method for treating multiple myeloma in a human patient, the method comprising orally administering a once daily dose of GDC-0199 to the patient, wherein a starting dose of the once daily dose comprises 400 mg of GDC-0199. 
     
     
         50 . The method of  claim 49 , wherein the method comprises administering the once daily dose of GDC-0199 in multiple dosing cycles. 
     
     
         51 . The method of  claim 50 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         52 . The method of  claim 50 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab. 
     
     
         53 . The method of  claim 52 , wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         54 . The method of  claim 53 , wherein the effective amount of the obinutuzumab is administered to the patient in combination with the GDC-0199 once in each dosing cycle for 6 to 7 dosing cycles. 
     
     
         55 . The method of  claim 52 , wherein the effective amount of the obinutuzumab is 1000 mg. 
     
     
         56 . The method of  claim 50 , wherein the GDC-0199 is administered in combination with an effective amount of dexamethasone, and wherein each dosing cycle of the multiple dosing cycles is 28 days. 
     
     
         57 . The method of  claim 49 , wherein the multiple myeloma is refractory multiple myeloma. 
     
     
         58 . The method of  claim 49 , wherein the method is continued until disease progression. 
     
     
         59 . The method of  claim 49 , further comprising administering GDC-0199 to patient in escalating doses, wherein a starting dose of the escalating doses is less than 400 mg per day and an ending dose of the escalating doses is 400 mg per day.